SAINT LAURENT, QUEBEC, and GREAT FALLS, VIRGINIA -- (MARKET WIRE) -- February 07, 2007 -- IntelGenx Technologies Corporation (OTCBB: IGXT)("IntelGenx" or the "Company") and Cary Pharmaceuticals today announced that enrollment of the subjects for the first Phase I pilot study for Cary Pharmaceutical's extended-release QuitPak® formulation has commenced. QuitPak® is Cary's proprietary combination product containing Bupropion and Mecamylamine and is intended as an alternative therapy in smoking cessation.
